Ranzani O, Alari A, Olmos S, Mila C, Rico A, Ballester J, Basagana X, Chaccour C, Dadvand P, Duarte-Salles T, Foraster M, Nieuwenhuijsen M, Sunyer J, Valentin A, Kogevinas M, Lazcano U, Avellaneda-Gomez C, Vivanco R, Tonne C. Long-term exposure to air pollution and severe COVID-19 in Catalonia: a population-based cohort study. Nat Commun. 2023 May 24;14(1):2916. doi: 10.1038/s41467-023-38469-7
Browning JC, Cartwright M, Thorla, Jr. I, Martin SA, Olayinka-Amao O, Maeda-Chubachi T. A patient-centered perspective of molluscum contagiosum as reported by B-SIMPLE4 clinical trial patients and caregivers: global impression of change and exit interview substudy results. Am J Clin Dermatol. 2023 Jan;24(1):119-33. doi: 10.1007/s40257-022-00733-9
Hollis K, Proctor C, McBride D, Balp MM, McLeod L, Hunter S, Tian H, Khalil S, Maurer M. Comparison of Urticaria Activity Score over 7 days (UAS7) values obtained from once-daily and twice daily versions: results from the ASSURE-CSU study. Am J Clin Dermatol. 2018 Apr;19(2):267-74. doi: 10.1007/s40257-017-0331-8
Camprodon-Rosanas E, Ribas-Fito N, Batlle-Vila S, Persavento C, Alvarez-Pedrerol M, Sunyer J, Forns J. Sluggish cognitive tempo: sociodemographic, behavioral, and clinical characteristics in a population of Catalan school children. J Atten Disord. 2017 Jun;21(8):632-41. doi: 10.1177/1087054716652477
Camprodon-Rosanas E, Ribas-Fito N, Batlle S, Persavento C, Alvarez-Pedrerol M, Sunyer J, Forns J. Association between sluggish cognitive tempo symptoms and attentional network and working memory in primary schoolchildren. J Atten Disord. 2017 Apr 1. doi: 10.1177/1087054717702245
Vilor-Tejedor N, Alemany S, Forns J, Caceres A, Murcia M, Macia D, Pujol J, Sunyer J, Gonzalez JR. Assessment of susceptibility risk factors for ADHD in imaging genetic studies. J Atten Disord. 2016 Aug 17.
Deal LS, Sleeper-Triplett J, DiBenedetti DB, Nelson L, McLeod L, Haydysch EE, Brown TM. Development and validation of the ADHD Benefits of Coaching Scale (ABCS). J Atten Disord. 2015 Mar;19(3):191-9. doi: 10.1177/1087054714558118
Ellis CN, Mordin MM, Adler EY. Effects of alefacept on health-related quality of life in patients with psoriasis: results from a randomized, placebo-controlled phase II trial. Am J Clin Dermatol. 2003 Feb 1;4(2):131-9.